Equipoise is the popular brand name for the veterinary injectable steroid boldenone undecylenate. It is a derivative of testosterone, which exhibits strong anabolic and moderately androgenic properties. The undecylenate ester greatly extends the activity of the drug (the undecylenate ester is only one carbon atom longer than decanoate), so that clinically injections would need to be repeated every three or four weeks. In the veterinary feild Equipoise is most commonly used on horses, exhibiting a pronounced effect on lean bodyweight, appetite and general disposition of the animal. As with all steroids, this compound shows a marked ability for increasing red blood cell production. In recent years this compound has become a favorite among athletes. Many consider it an ideal replacement to Deca-Durabolin.

The side effects of Equipoise are generally mild. The structure of boldenone does allow it to convert into estrogen, but it does not have an extremely high affinity to do so. If we look at aromatization studies, they suggest that its rate of estrogen conversion should be about half that of testosterone's. Water retention with this drug would therefore be slightly higher than that with Deca-Durabolin (with an estimated 20% conversion), but much less than we would find with a stronger compound as Testosterone. While there is still a chance of encountering an estrogen related side effect as such when using Equipoise, problems are usually not encountered at a moderate dosage level. Gynecomastia might become a problem, but usually only with very sensitive individuals or (again) with those using higher dosages. If estrogenic effects become a problem, the addition of Nolvadex should of course make the cycle more tolerable. An anti-aromatase such as Arimidex, Femara, or Amonasin would be a stronger option, however probably not necessary with such a mild drug.

Although typically dosage related, Equipoise can also produce distinct androgenic side effects. Oily skin, acne, increased aggression and hair loss are all possible with this compound. Women find this drug quite comfortable, virilization symptoms usually unheard of when taken at low doses. Boldenone does reduce to a more potent androgen (dihydroboldenone) via the 5alpha reductase enzyme (which produces DHT from testosterone), however its affinity for this interaction in the human body is low to nonexistent. Therefore the reductase inhibitor Proscar would not be of much use with Equipoise, as it would be blocking what is at best an insignificant path of metabolism for the steroid. Although this drug is relatively mild, it still has a depressive effect on endogenous testosterone levels, therefore a proper post cycle therapy HCG and Clomid/Nolvadex is needed at the conclusion of each cycle to avoid a "crash". A waiting time of around 3 weeks is required before starting PCT, enabling enough of the drug to clear one's system to make PCT effective.

In order to maintain stable blood levels, Equipoise should be injected at least once per week. It is most commonly used at a dosage of 400-600mg per week for men, 50-150 mg per week for women.

Page 1 of 2 :: First | Last :: Prev | 1 2 | Next